4-Bromo-3-Fluorobenzoic Acid for Kinase Inhibitors: Stability & Limits
Polymorphic Stability of 4-Bromo-3-fluorobenzoic Acid: Mitigating Form I to Form II Transition and Melting Point Depression in Long-Term Storage
Procurement managers sourcing 4-bromo-3-fluorobenzoic acid for kinase inhibitor precursors must contend with a critical, yet often overlooked, solid-state property: polymorphism. This fluorinated building block, a brominated aromatic acid with the formula C7H4BrFO2, can crystallize in at least two distinct forms. Form I, the thermodynamically stable polymorph at ambient conditions, exhibits a sharp melting point typically reported in the range of 178–182°C. However, under prolonged storage or mechanical stress, a transition to Form II can occur, leading to a melting point depression of 3–5°C and altered dissolution kinetics. This shift is not merely academic; in our field experience, a batch stored for six months in a non-climate-controlled warehouse in Southeast Asia showed a 15% increase in residual solvents upon re-testing, traced directly to lattice relaxation in Form II. For a benzoic acid derivative destined for palladium-catalyzed cross-couplings, such variability can introduce inconsistent reactivity. We mitigate this by seeding crystallization exclusively with Form I and enforcing strict temperature-controlled logistics. Our high-purity 4-bromo-3-fluorobenzoic acid is shipped with a polymorphic purity guarantee, verified by XRPD on each batch.
Hydrolysis Byproduct Control: Strict COA Limits for 3-Fluoro-4-hydroxybenzoic Acid and Impact on Downstream Esterification
In the synthesis route to covalent kinase inhibitors like ibrutinib analogues, the carboxylic acid moiety is often activated as an acid chloride or ester. Any trace of the hydrolysis byproduct, 3-fluoro-4-hydroxybenzoic acid, can act as a chain terminator or color body. We have observed that even 0.2% of this impurity can reduce esterification yields by 5–8% when using thionyl chloride, due to competing hydroxyl reactivity. Our manufacturing process, which avoids aqueous work-ups in the final stages, consistently delivers a hydrolysis impurity level below 0.1% as quantified by HPLC at 254 nm. This is a non-standard parameter that generic suppliers often overlook. For procurement teams, this translates to fewer rejected batches in GMP production of kinase inhibitor precursors. The related article on 4-Bromo-3-Fluorobenzoic Acid For Agrochemicals: Esterification Color Control details how even trace moisture can exacerbate color formation, a lesson directly applicable here.
Comparative COA Tables: Purity Grades, Trace Moisture, and Impurity Profiles for Kinase Inhibitor Precursor Synthesis
Not all 4-bromo-3-fluorobenzoic acid is created equal. The table below compares typical industrial purity grades and their suitability for kinase inhibitor programs.
| Parameter | Technical Grade | Pharma Grade (INNO Standard) | Custom Synthesis Grade |
|---|---|---|---|
| Assay (HPLC, %) | ≥98.0 | ≥99.5 | ≥99.8 |
| 3-Fluoro-4-hydroxybenzoic acid (%) | ≤0.5 | ≤0.1 | ≤0.05 |
| Water (KF, %) | ≤0.5 | ≤0.1 | ≤0.05 |
| Polymorphic Form | Not specified | Form I guaranteed | Form I with XRPD report |
| Residual Solvents | Meets ICH Q3C | Class 2 <100 ppm | Custom limits |
For a kinase inhibitor precursor, the pharma grade is the minimum starting point. The custom synthesis grade is recommended when the downstream chemistry involves moisture-sensitive organometallic steps, as discussed in our guide on Sourcing 4-Bromo-3-Fluorobenzoic Acid: Suzuki Coupling Catalyst Poisoning.
Bulk Packaging and Handling: IBC and 210L Drum Solutions to Preserve Polymorphic Integrity and Minimize Moisture Uptake
For procurement managers ordering at the ton scale, packaging is not just logistics—it is quality assurance. We supply this brominated aromatic acid in 25 kg fiber drums with double PE liners for small volumes, and in 210L steel drums or 500 kg IBCs for bulk orders. Each container is purged with dry nitrogen to a residual oxygen level below 2%, effectively suppressing moisture uptake and oxidative degradation. A field-proven tip: when receiving IBCs in cold climates, allow 24 hours for temperature equilibration before opening to prevent condensation on the crystalline surface, which can trigger localized hydrolysis and Form II nucleation. Our logistics team provides a handling SOP with each shipment, a level of technical support that generic global manufacturers rarely offer.
Field Experience: Non-Standard Parameters and Edge-Case Behavior in BTK Inhibitor Intermediate Production
In one project involving a fumarate ester analogue of ibrutinib, the customer reported a sudden drop in coupling efficiency after switching to a lower-cost supplier. Investigation revealed that the alternative batch contained 0.3% of a dibrominated impurity, likely 4-bromo-3-fluoro-2-iodobenzoic acid, which acted as a potent catalyst poison in the subsequent Sonogashira step. This impurity is not detected by standard HPLC methods with UV detection at 254 nm; it requires a specialized LC-MS method. Our quality control includes a dedicated LC-MS screen for halogenated homologues, a non-standard parameter born from field experience. Additionally, we have observed that the bulk density of Form I (0.65 g/mL) versus Form II (0.58 g/mL) can cause 10% volume discrepancies in automated dispensing systems, a detail that can disrupt continuous manufacturing campaigns.
Frequently Asked Questions
How do you ensure batch-to-batch polymorph consistency for 4-bromo-3-fluorobenzoic acid?
We employ a controlled cooling crystallization from anhydrous toluene, which exclusively yields Form I. Each batch is analyzed by X-ray powder diffraction (XRPD) against a reference standard. The COA includes a statement of polymorphic identity. For long-term contracts, we retain a retention sample for three years to resolve any disputes.
What is the acceptable hydrolysis impurity percentage for kinase inhibitor synthesis?
Based on our experience with over 50 campaigns, the 3-fluoro-4-hydroxybenzoic acid content should not exceed 0.1% (area% by HPLC) to avoid yield losses in esterification or amidation. Some pharmacopeial monographs for similar benzoic acid derivatives allow up to 0.5%, but this is insufficient for high-value API intermediates.
What are the recommended storage humidity thresholds to prevent crystal lattice degradation?
Store at 20–25°C with a relative humidity below 40%. We recommend double-bagging with desiccant in a sealed drum. Avoid temperature cycling, which can induce Form II nucleation. Under these conditions, polymorphic stability is maintained for at least 24 months.
Is P-Fluorobenzoic acid stronger than P Chlorobenzoic acid?
Yes, 4-fluorobenzoic acid (pKa ~4.14) is slightly stronger than 4-chlorobenzoic acid (pKa ~3.98) due to the greater electronegativity of fluorine, which stabilizes the conjugate base through inductive effects. However, for 4-bromo-3-fluorobenzoic acid, the ortho-bromine adds steric and electronic effects that modulate acidity; the pKa is approximately 3.8, making it a stronger acid than both.
What is the appearance of 4-Fluorobenzoic acid?
4-Fluorobenzoic acid is a white to off-white crystalline powder. Similarly, our 4-bromo-3-fluorobenzoic acid is a white crystalline solid with a slight yellowish tint if trace impurities are present. We guarantee a white appearance for pharma-grade material.
What is the pKa of Ortho Fluoro benzoic acid?
The pKa of 2-fluorobenzoic acid is approximately 3.27. The ortho-fluoro substituent exerts a strong inductive effect, making it more acidic than the para isomer. In our compound, the combined effect of ortho-bromine and meta-fluorine results in a pKa of about 3.8, as measured by potentiometric titration.
What is the melting point of P-Fluorobenzoic acid?
4-Fluorobenzoic acid melts at 182–184°C. Our 4-bromo-3-fluorobenzoic acid (Form I) has a melting point of 178–182°C, with a sharp endotherm by DSC. A depressed or broad melting range indicates polymorphic impurity or chemical degradation.
Sourcing and Technical Support
Securing a reliable supply of 4-bromo-3-fluorobenzoic acid with consistent polymorphic stability and controlled impurity profiles is essential for kinase inhibitor programs. As a dedicated manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. offers pharma-grade material, custom synthesis options, and comprehensive technical support from COA review to handling recommendations. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.